Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Комплексный интегративный геномный анализ диффузных глиом низкой степени злокачественности
2015-06-11
SCID: 54.1/297rf6jg
Discuss with AI
1p/19q codeletionIDH mutationTP53 and ATRX alterationsintegrative genomic analysislower-grade gliomas
Figures from the paper
Abstract (AI)
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Key Findings
1
IDH-mutant, 1p/19q-codeleted gliomas had the most favorable clinical outcomes and commonly contained CIC, FUBP1, NOTCH1, and TERT-promoter mutations.
2
Integrated genomewide analyses of 293 adult lower-grade gliomas identified three robust, nonoverlapping molecular subtypes with significant prognostic differences.
3
Molecular classification based on IDH, 1p/19q, and TP53 status was more accurate and consistent than histologic classification.
4
Most IDH-wild-type lower-grade gliomas showed genomic alterations and clinical behavior resembling primary glioblastoma.
5
Nearly all IDH-mutant gliomas without 1p/19q codeletion carried TP53 mutations (94%) and ATRX inactivation (86%).
Research Object
Adult diffuse lower-grade gliomas (WHO grade II and III)
Research Subject
Integrated genomic and epigenomic molecular classification of glioma subtypes and their associations with clinical outcomes
Publication Details
Publication Date
2015-06-11
Journal
New England Journal of Medicine
Publisher
Massachusetts Medical Society
ISSN
0028-4793
Cited by
3472
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest